Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$6.83 USD
+0.51 (8.07%)
Updated Aug 4, 2025 03:59 PM ET
After-Market: $6.83 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum C VGM
Fundamental Charts
About Dividend Yield (TTM)
Amicus Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
FOLD 6.83 +0.51(8.07%)
Will FOLD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FOLD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FOLD
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates
FOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
New Strong Sell Stocks for June 3rd
Other News for FOLD
JPMorgan Increases Price Target for Amicus Therapeutics (FOLD)
Amicus price target raised by $2 at JPMorgan, here's why
Amicus Therapeutics Inc (FOLD) Q2 2025 Earnings Call Highlights: Sustained Revenue Growth ...
Q2 2025 Amicus Therapeutics Inc Earnings Call Transcript
Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200